Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Biology
• Drug Discovery

Background:

• Protein neddylation, catalyzed by E1 NEDD8-activating enzyme (NAE), E2, and E3 ligases, modifies cullin proteins.
• Neddylation activates cullin-RING ligases (CRLs), essential for degrading regulatory proteins and controlling cell processes.
• Aberrant neddylation and CRL activation are implicated in human cancers, making them therapeutic targets.

Purpose of the Study:

• To investigate the therapeutic potential of targeting protein neddylation in cancer.
• To evaluate the efficacy and mechanisms of MLN4924, a NAE inhibitor, in preclinical and clinical settings.

Main Methods:

• Utilized MLN4924, a small molecule inhibitor of NAE, to block CRL activity.
• Assessed MLN4924's effects on tumor cell growth, apoptosis, senescence, and autophagy in preclinical models.
• Monitored clinical trials evaluating MLN4924's safety and efficacy in human solid tumors.

Main Results:

• MLN4924 effectively suppresses tumor cell growth by inducing apoptosis, senescence, and autophagy.
• MLN4924 sensitizes cancer cells to chemoradiation therapies in a context-dependent manner.
• Cancer cells can develop resistance to MLN4924 through target mutations.

Conclusions:

• Targeting protein neddylation, particularly cullin neddylation, presents a promising anticancer strategy.
• MLN4924 demonstrates significant preclinical efficacy and is under investigation in clinical trials.
• Further development of neddylation inhibitors targeting E2 and E3 enzymes is ongoing.